Pediatrix Medical Group, Inc. (MD) Key Metrics
MD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.22B
- Enterprise value
- $2.32B
- P/E (TTM)
- 13.1 10-yr median 16.8
- Forward P/E
- 9.3
- PEG ratio
- 0.24
- Price / sales
- 1.1 10-yr median 1.1
- Price / book
- 2.4 10-yr median 1.6
- EV / EBITDA
- 8.2 10-yr median 11.9
- Dividend yield
- —
- Beta
- 0.61
MD key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMD valuation Price multiples at each fiscal year-end price.
MD returns How much profit the business earns on the capital it uses.
MD per-share figures Results divided by the shares outstanding at year-end.
MD financial health Debt, liquidity and how easily interest is covered.
MD efficiency & capital use Working capital cycle and where the cash goes.
MD valuation history
MD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MD cash returned to shareholders
MD price vs earnings per share
MD key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.82B | $1.09B | $764.5M | $1.25B | $2.35B | $2.10B | $2.34B | $3.02B | $5.01B | $6.25B |
| Enterprise value | $1.98B | $1.41B | $1.29B | $1.86B | $2.93B | $2.68B | $3.95B | $4.94B | $6.79B | $7.89B |
| P/E ratio | 11.0 | — | — | 18.8 | 18.0 | — | — | 11.3 | 15.6 | 19.2 |
| Price / sales | 1.0 | 0.5 | 0.4 | 0.6 | 1.2 | 1.2 | 1.3 | 0.8 | 1.4 | 2.0 |
| Price / book | 2.1 | 1.4 | 0.9 | 1.4 | 2.6 | 2.8 | 1.6 | 1.0 | 1.6 | 2.3 |
| Price / free cash flow | 7.2 | 5.9 | 7.4 | 9.1 | 52.9 | 11.9 | 7.4 | 12.5 | 10.8 | 15.4 |
| Price / operating cash flow | 6.7 | 5.3 | 5.6 | 7.5 | 30.6 | 10.3 | 6.8 | 10.4 | 9.8 | 14.1 |
| EV / sales | 1.0 | 0.7 | 0.6 | 0.9 | 1.5 | 1.5 | 2.2 | 1.4 | 2.0 | 2.5 |
| EV / EBITDA | 7.2 | — | 43.1 | 11.9 | 12.4 | 18.3 | 19.4 | 10.5 | 11.6 | 11.9 |
| EV / free cash flow | 7.9 | 7.6 | 12.4 | 13.6 | 65.9 | 15.2 | 12.6 | 20.5 | 14.7 | 19.5 |
| Earnings yield | 9.1% | −9.1% | −7.9% | 5.3% | 5.6% | −37.9% | −64.0% | 8.9% | 6.4% | 5.2% |
| Free cash flow yield | 13.9% | 16.9% | 13.6% | 11.0% | 1.9% | 8.4% | 13.4% | 8.0% | 9.2% | 6.5% |
| Dividend yield | — | — | 61.5% | — | — | 25.1% | 74.6% | 73.6% | 56.8% | 31.1% |
| Shareholder yield (dividends + buybacks) | 4.8% | 0.2% | 61.6% | 7.1% | 0.2% | 25.5% | 80.8% | 83.5% | 58.2% | 32.0% |
| Share price at fiscal year-end | $21.39 | $13.12 | $9.30 | $14.86 | $27.21 | $24.54 | $27.79 | $33.00 | $53.44 | $66.66 |
| Per share | ||||||||||
| Revenue per share | $22.45 | $24.16 | $24.27 | $23.44 | $22.11 | $20.26 | $21.13 | $39.81 | $36.90 | $33.97 |
| Earnings per share | $1.94 | −$1.19 | −$0.73 | $0.79 | $1.52 | −$9.31 | −$17.78 | $2.93 | $3.42 | $3.47 |
| Operating cash flow per share | $3.18 | $2.48 | $1.67 | $1.98 | $0.89 | $2.39 | $4.11 | $3.16 | $5.46 | $4.74 |
| Free cash flow per share | $2.96 | $2.21 | $1.27 | $1.63 | $0.51 | $2.05 | $3.74 | $2.63 | $4.93 | $4.32 |
| Cash per share | $5.86 | $4.18 | $2.16 | $1.23 | $5.64 | $14.36 | $2.16 | $0.64 | $0.75 | $0.71 |
| Book value per share | $10.15 | $9.18 | $10.33 | $10.60 | $10.37 | $8.73 | $17.79 | $33.71 | $32.72 | $29.46 |
| Tangible book value per share | −$4.83 | −$5.87 | −$6.77 | −$7.83 | −$7.30 | −$8.85 | −$0.11 | −$23.90 | −$23.19 | −$21.25 |
| Dividends per share | — | — | $5.72 | — | — | $6.15 | $20.74 | $24.27 | $30.37 | $20.70 |
| Capex per share | $0.22 | $0.26 | $0.41 | $0.35 | $0.37 | $0.34 | $0.38 | $0.53 | $0.53 | $0.42 |
| Debt per share | $7.74 | $7.95 | $8.54 | $8.52 | $12.33 | $21.08 | $21.28 | $21.55 | $19.77 | $18.20 |
| Shares outstanding | 85.3M | 83.3M | 82.2M | 84.1M | 86.4M | 85.6M | 84.2M | 91.6M | 93.7M | 93.7M |
| Change in shares outstanding | +2.3% | +1.4% | −2.3% | −2.7% | +1.0% | +1.6% | −8.0% | −2.3% | +0.0% | −0.3% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 20.3% | −12.3% | −6.9% | 7.4% | 15.9% | −70.9% | −65.3% | 8.7% | 11.0% | 12.5% |
| Return on invested capital (ROIC) | 16.8% | −4.4% | 0.4% | 8.9% | 11.6% | 2.2% | 3.0% | 6.6% | 8.1% | 9.0% |
| Return on assets (ROA) | 7.5% | −4.5% | −2.6% | 2.6% | 4.3% | −21.3% | −29.7% | 4.6% | 5.7% | 6.6% |
| Return on tangible assets | 17.1% | −11.0% | −7.4% | 8.3% | 11.0% | −43.2% | −56.8% | 40.9% | 51.1% | 55.3% |
| Free cash flow margin | 13.2% | 9.2% | 5.2% | 7.0% | 2.3% | 10.1% | 17.7% | 6.6% | 13.4% | 12.7% |
| Income quality (OCF / net income) | 1.64 | — | — | 2.52 | 0.59 | — | — | 1.08 | 1.60 | 1.37 |
| Financial health | ||||||||||
| Total debt | $660.3M | $662.3M | $701.6M | $717.1M | $1.07B | $1.80B | $1.79B | $1.97B | $1.85B | $1.71B |
| Cash & short-term investments | $499.7M | $348.5M | $177.7M | $103.1M | $487.1M | $1.23B | $182.4M | $58.7M | $70.5M | $67.0M |
| Net debt | $160.6M | $313.8M | $523.9M | $614.0M | $578.7M | $576.0M | $1.61B | $1.92B | $1.78B | $1.64B |
| Debt / equity | 0.76 | 0.87 | 0.83 | 0.80 | 1.19 | 2.41 | 1.20 | 0.64 | 0.60 | 0.62 |
| Debt / assets | 0.29 | 0.31 | 0.32 | 0.31 | 0.39 | 0.54 | 0.43 | 0.33 | 0.32 | 0.32 |
| Net debt / EBITDA | 0.59 | — | 17.53 | 3.92 | 2.45 | 3.94 | 7.91 | 4.09 | 3.03 | 2.48 |
| Current ratio | 1.66 | 1.47 | 1.24 | 1.00 | 1.97 | 3.49 | 1.35 | 1.40 | 1.43 | 1.44 |
| Quick ratio | 1.66 | 1.47 | 1.21 | 1.00 | 1.97 | 3.49 | 1.35 | 1.40 | 1.43 | 1.44 |
| Interest coverage | 6.4 | -1.7 | 0.2 | 4.4 | 3.0 | 0.9 | 1.4 | 4.8 | 6.4 | 9.1 |
| Working capital | $304.6M | $205.5M | $94.5M | $1.0M | $413.2M | $1.11B | $189.7M | $188.1M | $189.2M | $179.2M |
| Invested capital | $1.03B | $1.08B | $1.37B | $1.51B | $1.48B | $1.32B | $3.11B | $5.00B | $4.85B | $4.40B |
| Tangible asset value | −$411.7M | −$489.3M | −$556.3M | −$659.0M | −$630.3M | −$756.9M | −$9.4M | −$2.19B | −$2.17B | −$1.99B |
| Net current asset value | −$617.3M | −$748.2M | −$887.3M | −$1.03B | −$985.3M | −$1.05B | −$1.92B | −$2.19B | −$2.17B | −$1.99B |
| Graham number | $21.05 | — | — | $13.71 | $18.81 | — | — | $47.16 | $50.16 | $47.94 |
| Graham net-net per share | −$8.20 | −$10.02 | −$11.88 | −$13.44 | −$12.75 | −$13.90 | −$25.39 | −$26.29 | −$25.10 | −$22.84 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $470.0M | — | — | $526.3M | $1.75B | $2.22B | $2.85B | $1.94B |
| Share buybacks (net) | $86.7M | $1.7M | $919,000 | $88.5M | $4.7M | $8.5M | $145.3M | $302.2M | $70.2M | $61.8M |
| Dividend payout ratio | — | — | — | — | — | — | — | 827.7% | 888.3% | 597.1% |
| Dividends + buybacks / free cash flow | 34.3% | 0.9% | 452.8% | 64.5% | 10.6% | 304.1% | 601.3% | — | 631.1% | 494.9% |
| Capex / revenue | 1.0% | 1.1% | 1.7% | 1.5% | 1.7% | 1.7% | 1.8% | 1.3% | 1.4% | 1.2% |
| Capex / operating cash flow | 6.8% | 10.7% | 24.3% | 17.8% | 42.0% | 14.1% | 9.2% | 16.9% | 9.6% | 8.8% |
| Capex / depreciation | 0.85 | 0.68 | 0.92 | 0.83 | 1.00 | 1.01 | 0.40 | 2.01 | 0.48 | 0.44 |
| Stock-based compensation / revenue | 0.9% | 0.6% | 0.6% | 0.8% | 1.0% | 2.3% | 2.0% | 1.1% | 0.9% | 1.1% |
| SG&A / revenue | 12.6% | 11.8% | 11.4% | 11.7% | 13.8% | 14.4% | 13.7% | 11.9% | 12.1% | 11.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 49.1 | 50.1 | 52.8 | 56.7 | 53.3 | 71.2 | 96.5 | 50.6 | 52.7 | 53.9 |
| Days of inventory on hand | — | — | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Days payables outstanding | 10.6 | 9.5 | 7.7 | 8.3 | 12.6 | 13.5 | 9.5 | 4.5 | 4.7 | 4.3 |
| Cash conversion cycle (days) | 38.5 | 40.6 | 46.6 | 48.4 | 40.7 | 57.6 | 87.0 | 46.1 | 48.0 | 49.6 |
| Receivables turnover | 7.43 | 7.29 | 6.92 | 6.44 | 6.85 | 5.13 | 3.78 | 7.22 | 6.92 | 6.77 |
| Payables turnover | 34.48 | 38.47 | 47.35 | 43.94 | 29.00 | 26.99 | 38.41 | 80.91 | 77.91 | 85.23 |
| Inventory turnover | — | — | 232.62 | 1,504,988,000.00 | 1,397,949,000.00 | 1,284,630,000.00 | 1,276,670,000.00 | 2,657,616,000.00 | 2,458,252,000.00 | 2,149,636,000.00 |
| Asset turnover | 0.87 | 0.92 | 0.87 | 0.78 | 0.63 | 0.46 | 0.35 | 0.62 | 0.62 | 0.64 |
| Average receivables | $257.5M | $276.2M | $288.3M | $306.4M | $279.0M | $338.1M | $470.5M | $505.4M | $499.6M | $470.0M |
| Average payables | $41.8M | $40.5M | $33.2M | $34.3M | $48.2M | $47.6M | $33.2M | $32.8M | $31.6M | $25.2M |
| Average inventory | — | — | $6.8M | $1 | $1 | $1 | $1 | $1 | $1 | $1 |
| Intangibles / total assets | 56.9% | 58.3% | 63.3% | 66.0% | 56.1% | 44.9% | 36.4% | 88.9% | 89.3% | 89.0% |
Computed from MD's annual financial statements (latest annual report filed February 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MD valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Pediatrix Medical traded at 11.0 times earnings, against a 10-year median of 16.8. Based on the latest twelve months, the trailing P/E is 13.1 and the forward P/E is 9.3. Pediatrix Medical earned a return on equity of 20.3% and a return on invested capital of 16.8% in fiscal 2025. It ended the year with $660.3 million of debt and $499.7 million in cash and short-term investments, net debt of $160.6 million. It returned $86.7 million to shareholders: $0 in dividends and $86.7 million in share buybacks, 34% of free cash flow. The share count fell 9.0% from 93.7M to 85.3M over 9 years.
See the MD income statement, the MD chart for price history, or the MD stock overview for the latest quote and news.
MD key metrics FAQ
What is Pediatrix Medical's P/E ratio?
Pediatrix Medical's trailing P/E ratio is 13.1 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 9.3. At the end of fiscal 2025 it was 11.0, compared with a 10-year median of 16.8.
What is Pediatrix Medical's EV/EBITDA?
Pediatrix Medical's enterprise value was 7.2 times EBITDA at the end of fiscal 2025 (enterprise value $2.0 billion, EBITDA $274.2 million); the current EV/EBITDA is 8.2.
What is Pediatrix Medical's return on equity?
Pediatrix Medical's return on equity (ROE) was 20.3% in fiscal 2025: net income of $165.4 million on average shareholders' equity of $815.4 million.
What is Pediatrix Medical's ROIC?
Pediatrix Medical's return on invested capital was 16.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Pediatrix Medical have?
Pediatrix Medical had total debt of $660.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.76 and $160.6 million of net debt (0.59 times EBITDA).
Does Pediatrix Medical buy back its shares?
Yes. Pediatrix Medical spent $86.7 million on net share repurchases in fiscal 2025 Shares outstanding changed +2.3% over the year, to 85.3M..
What is Pediatrix Medical's free cash flow yield?
Pediatrix Medical generated $252.6 million of free cash flow in fiscal 2025, a free cash flow yield of 13.9% on its market value at year-end ($1.8 billion).
What is Pediatrix Medical's current ratio?
Pediatrix Medical's current ratio was 1.66 at the end of fiscal 2025: current assets were 1.66 times current liabilities.